Navigation Links
Oramed Patent Being Granted in China for Oral Administration of Proteins
Date:5/11/2016

JERUSALEM, May 11, 2016 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that an official Notification of Granting Patent Right was issued for the Company's patent for its invention titled "Methods and Compositions for Oral Administrations of Proteins" by the State Intellectual Property Office of the People's Republic of China.

About Oramed Pharmaceuticals 

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

For more information, the content of which is not part of this press release, please visit www.oramed.com

Forward-looking statements: This press release contains forward-looking statements. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the SEC.

 

Company Contact
Oramed Pharmaceuticals
Estee Yaari
Office: +972-2-566-0001 ext. 2
US: 1-718-831-2512 ext. 2
Email: estee@oramed.com


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Oramed to Present at PIONEERS 2016, Presented by Joseph Gunnar
2. Oramed Receives Patent Term Adjustment Extending the Term of Its U.S. Patent
3. Oramed Completes Phase IIb Oral Insulin Study
4. Oramed Patent Granted in India for Oral Administration of Proteins
5. Oramed Pharmaceuticals Shareholder Letter
6. Oramed Announces Closing of Licensing and Investment Deal with HTIT for Oral Insulin Capsule in China
7. Oramed Signs up to $50 Million Licensing and Investment Agreements for Oral Insulin Capsule in China
8. Oramed Patent Allowed in the US for Oral Administration of Proteins
9. Oramed Completes Randomization of Over 50% of Patients in Phase IIb Oral Insulin Study
10. Oramed to Present at the Rodman & Renshaw Global Investment Conference
11. Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2020)... (PRWEB) , ... May 29, 2020 , ... ... following statement in response to the U.S. announcement that it will terminate its ... the Administration’s announcement that it plans to terminate its relationship with the World ...
(Date:5/30/2020)... ... May 30, 2020 , ... Pregnancy is stressful already, ... issues related to COVID-19. Recently, Wellness Expert Jamie Hess teamed with One A ... pregnancy and postpartum. , A video accompanying this announcement is available at: ...
(Date:5/28/2020)... ... May 28, 2020 , ... May is Talking is Power Month, a national ... care about them. The focus of Power to Decide’s #TalkingIsPower campaign reminds parents, trusted ... Power to Decide’s Mackenzie Piper, MPH, CHES, provides five strategies parents, trusted adults and ...
Breaking Medicine Technology:
(Date:5/21/2020)... ... May 21, 2020 , ... In ... will be lifted on May 28th and all businesses will be required to ... returning back to work. , As an essential business, AmeriCare Medical began this ...
(Date:5/21/2020)... ... May 21, 2020 , ... The Rise of Mental Health and Substance Abuse ... complications and adjustments, needless to say, more complications. With rising deaths, more confirmed cases ... it can be hard to escape and find peace. Adding to these persistent stressors ...
(Date:5/21/2020)... , ... May 21, 2020 , ... A new ... Medicine Group, details over 90 companies involved in the point of care test industry. ... facilities for preliminary testing, COVID-19 has made point-of-care more important than in the past, ...
(Date:5/17/2020)... , ... May 18, 2020 , ... ... cell therapy program at its Tijuana regenerative clinic. There are two program options ... and safe cell counts. , While it is unclear exactly what causes Autism ...
(Date:5/16/2020)... ... May 15, 2020 , ... On May 21, T1V will host a webinar featuring Dr. ... USC, and a contributor to CBS news, as we address COVID-19 and the impact on ... parts of the country since March, many questions are left unanswered as we look at ...
Breaking Medicine News(10 mins):